A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : MS / multiple sclerosis

[Related PubMed/MEDLINE]
Total Number of Papers: 32004
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   MS  (>> Co-occurring Abbreviation)
Long Form:   multiple sclerosis
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 'Prototypical' proinflammatory cytokine (IL-1) in multiple sclerosis: role in pathogenesis and therapeutic targeting. CNS, IL
2020 18F-THK5351 PET Can Identify Astrogliosis in Multiple Sclerosis Plaques. ---
2020 2-arachidonoylglycerol reduces chondroitin sulphate proteoglycan production by astrocytes and enhances oligodendrocyte differentiation under inhibitory conditions. 2-AG, CSPGs, OPC
2020 A 30-Year Clinical and Magnetic Resonance Imaging Observational Study of Multiple Sclerosis and Clinically Isolated Syndromes. EDSS, RRMS
2020 A current understanding of multiple sclerosis. ---
2020 A roadmap to precision medicine for multiple sclerosis. ---
2020 A Tunable-Q wavelet transform and quadruple symmetric pattern based EEG signal classification method. EEG, k-NN, NCA, PD, QSP, TQWT
2020 Aberrant DNA methylation profile exacerbates inflammation and neurodegeneration in multiple sclerosis patients. ---
2020 Ac-SDKP ameliorates the progression of experimental autoimmune encephalomyelitis via inhibition of ER stress and oxidative stress in the hippocampus of C57BL/6 mice. CHOP, EAE, ER, MOG, PDI, ROS
10  2020 Acteoside ameliorates experimental autoimmune encephalomyelitis through inhibiting peroxynitrite-mediated mitophagy activation. AC, CNS, EAE, RR
11  2020 Air pollution, a possible risk factor for multiple sclerosis. ---
12  2020 Alemtuzumab-induced thyroid events in multiple sclerosis: a systematic review and meta-analysis. ALZ, ATEs, CI, GD
13  2020 An analysis of the relationship of character strengths and quality of life in persons with multiple sclerosis. QOL
14  2020 An argument for broad use of high efficacy treatments in early multiple sclerosis. ---
15  2020 Antibody response against HERV-W in patients with MOG-IgG associated disorders, multiple sclerosis and NMOSD. AQP4, NMOSD
16  2020 Antibody signatures in patients with histopathologically defined multiple sclerosis patterns. AQP1
17  2020 Are multi-contrast magnetic resonance images necessary for segmenting multiple sclerosis brains? A large cohort study based on deep learning. CSF, DSC, FPR, TPR, WM
18  2020 Assessing Barriers to Adherence with the Use of Dimethyl Fumarate in Multiple Sclerosis. AE, DMF, DMT
19  2020 Assessment of CCL27 and IL-11 in Multiple Sclerosis Patients Treated with Interferon-beta and Glatiramer Acetate. ELISA, GA, IFN, IL, RRMS
20  2020 Assessment of the Burden of Multiple Sclerosis Patients' Caregivers in Saudi Arabia. ZBI
21  2020 Association between FAS gene -670 A/G and -1377 G/A polymorphisms and the risk of autoimmune diseases: a meta-analysis. CIs, HT, ORs, SLE, SSc
22  2020 Association between urinary symptom severity and white matter plaque distribution in women with multiple sclerosis. AUASI, LFL, PV, RCG, RLL
23  2020 Astrocyte-T cell crosstalk regulates region-specific neuroinflammation. CNS
24  2020 Automated Assessment of Oral Diadochokinesis in Multiple Sclerosis Using a Neural Network Approach: Effect of Different Syllable Repetition Paradigms. AMR, SMR
25  2020 Automated volumetric assessment with artificial neural networks might enable a more accurate assessment of disease burden in patients with multiple sclerosis. ANN, CCC, CE
26  2020 Barriers to access and utilization of multiple sclerosis care services in a large cohort of Latin American patients. DMTs, LATAM, LATAM, PwMS
27  2020 Biological models in multiple sclerosis. ---
28  2020 Biosensors to monitor MS activity. AI
29  2020 Blockade of Arginine Vasopressin receptors prevents blood-brain barrier breakdown in Experimental Autoimmune Encephalomyelitis. BBB, NIL
30  2020 BMI and low vitamin D are causal factors for multiple sclerosis: A Mendelian Randomization study. BMI
31  2020 C-type lectin receptors Mcl and Mincle control development of multiple sclerosis-like neuroinflammation. CLRs, EAE, PRRs
32  2020 Calling Out MS Fatigue: Feasibility and Preliminary Effects of a Pilot Randomized Telephone-Delivered Exercise Intervention for Multiple Sclerosis Fatigue. ---
33  2020 Can CSF biomarkers predict future MS disease activity and severity? CSF, GFAP, NfL, sNfL
34  2020 Cannabinoid CB2 Receptor Functional Variation (Q63R) Is Associated with Multiple Sclerosis in Iranian Subjects. CNR2, CNS
35  2020 Cerebrospinal fluid free light chains compared to oligoclonal bands as biomarkers in multiple sclerosis. CIS, CSF, FLC, OCB
36  2020 Cholesterol and neurodegeneration: longitudinal changes in serum cholesterol biomarkers are associated with new lesions and gray matter atrophy in multiple sclerosis over 5 years of follow-up. HDL-C
37  2020 Chronic illness and sustainable careers: How individuals with multiple sclerosis negotiate work transitions in a middle-income country. ---
38  2020 Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis. ADEM, MOG, MOG-IgG, MOGAD
39  2020 Clinical Use of kappa Free Light Chains Index as a Screening Test for Multiple Sclerosis. CSF, kappaFLCi, kappaFLCi, OCBs
40  2020 Cognitive functions in pediatric multiple sclerosis: 2-years follow-up. ---
41  2020 Comorbidity in multiple sclerosis: its temporal relationships with disease onset and dose effect on mortality. CI
42  2020 Comparison of Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis. NMOSD
43  2020 Comparison of the effectiveness of a tailored cognitive behavioural therapy with a supportive listening intervention for depression in those newly diagnosed with multiple sclerosis (the ACTION-MS trial): protocol of an assessor-blinded, active comparator, randomised controlled trial. CBT, SL
44  2020 Comparison of The Expression of miR-326 between Interferon beta Responders and Non-Responders in Relapsing-Remitting Multiple Sclerosis. CNS, DMTs, IFN-beta, miRNAs, PBMCs, RRMS, RT-PCR, Th17
45  2020 Concurrence of multiple sclerosis, oligodendroglioma, and autosomal recessive cerebellar ataxia with spasticity in the same patient: A challenging diagnosis. ---
46  2020 Consensus document on the multidisciplinary management of neurogenic lower urinary tract dysfunction in patients with multiple sclerosis. GA, NLUTD
47  2020 Consistent control of disease activity with fingolimod versus IFN beta-1a in paediatric-onset multiple sclerosis: further insights from PARADIGMS. ARR, CDP, EDSS, IFN
48  2020 Continuous reorganization of cortical information flow in multiple sclerosis: A longitudinal fMRI effective connectivity study. CBN, EC, EDSS, FSMC, HC, TPDC
49  2020 Cortical Excitability through Anodal Transcranial Direct Current Stimulation: a Computational Approach. HD-tDCS, MRI, tDCS
50  2020 CXCR2 antagonism promotes oligodendrocyte precursor cell differentiation and enhances remyelination in a mouse model of multiple sclerosis. CPZ, CXCR2, OPCs
51  2020 Dalfampridine benefits ambulation but not cognition in multiple sclerosis. 6MW, FDA
52  2020 Deep Learning for Predicting Enhancing Lesions in Multiple Sclerosis from Noncontrast MRI. AUCs
53  2020 Developmental Venous Anomalies are More Common in Patients with Multiple Sclerosis and Clinically Isolated Syndrome : Coincidence or Relevant? CIS, CSF, DVA, MRI, RRMS
54  2020 Diffusion tensor imaging tractography reveals altered fornix in all diagnostic subtypes of multiple sclerosis. DTI, FA, PPMS, RRMS
55  2020 Do clinical trials for new disease modifying treatments include real world patients with multiple sclerosis? RCT, RWS
56  2020 Do patients with multiple sclerosis benefit from semi-immersive virtual reality? A randomized clinical trial on cognitive and motor outcomes. CG, EG, sVRT
57  2020 Do Secondary Progressive Multiple Sclerosis patients benefit from Computer- based cognitive neurorehabilitation? A randomized sham controlled trial. BDI-FS, BICAMS, CG, CR, HBCACR, RRMS, SPMS, VAS
58  2020 EBNA1, EBNA2, and EBNA3 link Epstein-Barr virus and hypovitaminosis D in multiple sclerosis pathogenesis. EBV
59  2020 Ecological impact of isolated cognitive relapses in MS. ICRs, MSNQ-I, RRMS
60  2020 Effect of generic glatiramer acetate on spending and use of drugs for multiple sclerosis. CI, DMTs
61  2020 Effects of interferon and glatiramer acetate on cytokine patterns in multiple sclerosis patients. GA, IFN-gamma, IL-5, RR, TGF-beta
62  2020 Environmental enrichment improves cognitive symptoms and pathological features in a focal model of cortical damage of multiple sclerosis. EE, PPMS, RRMS
63  2020 Epstein Barr virus nuclear antigen 1 (EBNA-1) peptides recognized by adult multiple sclerosis patient sera induce neurologic symptoms in a murine model. EAE, EBNA-1, EBNA1, EBV, MBP
64  2020 Evaluation of NeuroPage as a memory aid for people with multiple sclerosis: A randomised controlled trial. ---
65  2020 Evaluation of The Expression Levels of Three Long Non-Coding RNAs in Multiple Sclerosis. EDSS, lncRNAs, qRT-PCR, ROC
66  2020 Exercise in multiple sclerosis and its models: Focus on the central nervous system outcomes. CNS
67  2020 Exploring uncertainty measures in deep networks for Multiple sclerosis lesion detection and segmentation. MC
68  2020 Expression of LEP, LEPR and PGC1A genes is altered in peripheral blood mononuclear cells of patients with relapsing-remitting multiple sclerosis. LEP, LEPR, PGC1A
69  2020 Extensive subpial cortical demyelination is specific to multiple sclerosis. ADEM, NMO, PML, SSPE
70  2020 Failed B cell survival factor trials support the importance of memory B cells in multiple sclerosis. ---
71  2020 Fatigue in multiple sclerosis: The role of thalamus. ---
72  2020 Fibrotic scar after experimental autoimmune encephalomyelitis inhibits oligodendrocyte differentiation. EAE, ECM, OPCs
73  2020 Functional relevance of the multi-drug transporter abcg2 on teriflunomide therapy in an animal model of multiple sclerosis. ABC, CSFE, EAE, KO, TERI, WT
74  2020 Gene Therapy with Single-Subunit Yeast NADH-Ubiquinone Oxidoreductase (NDI1) Improves the Visual Function in Experimental Autoimmune Encephalomyelitis (EAE) Mice Model of Multiple Sclerosis (MS). EAE, OCT, RGC, scAAV
75  2020 Genetic Alterations in Patients with Two Clinical Phenotypes of Multiple Sclerosis. MNC, RRMS, SPMS
76  2020 Genetic and gene expression signatures in multiple sclerosis. ---
77  2020 Genetic and Molecular Biology of Multiple Sclerosis Among Iranian Patients: An Overview. ---
78  2020 Genetic model of MS severity predicts future accumulation of disability. GeM-MSS, MS-DSS
79  2020 Hemodynamics of cerebral veins analyzed by 2d and 4d flow mri and ultrasound in healthy volunteers and patients with multiple sclerosis. CCSVI, StS, VCM
80  2020 Herpes viruses in optic neuritis: Similar to Bell's palsy. ON
81  2020 High fat diet consumption results in mitochondrial dysfunction, oxidative stress, and oligodendrocyte loss in the central nervous system. HFD
82  2020 Hippocampal Neurogenesis and Neural Circuit Formation in a Cuprizone-Induced Multiple Sclerosis Mouse Model. NSCs
83  2020 Histogram analysis of apparent diffusion coefficient and fluid-attenuated inversion recovery in discriminating between enhancing and nonenhancing lesions in multiple sclerosis. ADC, AUC, ELs, NAWM, NELs, ROC, T2-FLAIR, WM
84  2020 HIV-1 Tat protein attenuates the clinical course of experimental autoimmune encephalomyelitis (EAE). AIDS, BBB, EAE, HIV, MOG35-55
85  2020 HLA DR2b-binding peptides from human endogenous retrovirus envelope, Epstein-Barr virus and brain proteins in the context of molecular mimicry in multiple sclerosis. EBV, HERV, HERV env
86  2020 Identification of common key genes and pathways between type 1 diabetes and multiple sclerosis using transcriptome and interactome analysis. CSF, PBMCs, QQPPI, T1D
87  2020 Immune cell modulation of oligodendrocyte lineage cells. iOLs, iOPCs, OPCs
88  2020 Immune reconstitution therapies: concepts for durable remission in multiple sclerosis. IRTs
89  2020 Impact of multiple sclerosis phenotypes on burden of disease in Finland. EDSS, FSS, MSIS-29, PPMS, SPMS
90  2020 Impaired Expression of Tetraspanin 32 (TSPAN32) in Memory T Cells of Patients with Multiple Sclerosis. EAE, HD, MOG, PBMCs, TSPAN32
91  2020 Incidence and temporal trends of co-occurring personality disorder diagnoses in immune-mediated inflammatory diseases. IBD, IMID, IRR, PDs, RA
92  2020 Increased HLA-DR expression and cortical demyelination in MS links with HLA-DR15. NAGM
93  2020 Increased mental health care use by mothers of children with multiple sclerosis. CI, RR
94  2020 Increased plasma levels of mitochondrial DNA and pro-inflammatory cytokines in patients with progressive multiple sclerosis. HMGB1, mtDNA, PP, SP
95  2020 Informing Medication Discontinuation Decisions among Older Adults with Relapsing-Onset Multiple Sclerosis. DMDs, EDSS, QALYs
96  2020 Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis. CNS, CSEA, CSF
97  2020 Interrogation of the Multiple Sclerosis Prodrome Using High-Dimensional Health Data. aOR
98  2020 Is there a new place for mitoxantrone in the treatment of multiple sclerosis? EDSS, IMTs, MRI, MTX
99  2020 Ketogenic diet and fasting diet as Nutritional Approaches in Multiple Sclerosis (NAMS): protocol of a randomized controlled study. FDs, KDs, NAMS, SD
100  2020 Laquinimod ameliorates secondary brain inflammation. PET